Hyperuricemia
Conditions
Interventions
Lactobacillus rhamnosus CCFM1131:Lactobacillus rhamnosus CCFM1131
placebo:placebo
health group:none
Sponsors
Yixing People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. He/She meets the diagnostic criteria of hyperuricemia; 2. Aged 18-65 years, male or female; 3. The blood uric acid level was detected twice on an empty stomach on different days, which was higher than 420 in men µmol/L, higher than 360 for women µmol/L; 4. Good compliance, able to comply with the requirements of clinical trials; 5. The subject or guardian has signed the informed consent form; 6. The patients filled in the written informed consent form, the International Physical Activity Scale and the dietary structure questionnaire, and promised to cooperate with the study during the whole trial period.
Exclusion criteria
Exclusion criteria: (1) Converted ethanol intake >40 g/week; (2) Regular intake of non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and corticosteroids, antineoplastics, anti-tuberculosis drugs, and some herbs and minerals (big maple seeds/diarsenic triazide) in the past 6 months; (3) Abuse of narcotics, psychotropic substances and cigarettes in the past 6 months; (4) Ingestion within the last 6 months of drugs causing gastric acid deficiency, amiodarone, sodium valproate, prednisone, tamoxifen, percocet and methotrexate, hepatic fat-inducing drugs, hormonal drugs, statins, antihypertensives, and antisecretory drugs of ursodeoxycholic acid. (5) Supplementation with nutrients such as probiotics, multivitamins/minerals, antioxidants and omega-3 at least twice a week for the duration of the study or within the last 3 months. (6) Patients with acute attacks of gout. (7) Patients with secondary hyperuricaemia caused by glomerular disease, lead poisoning, haematological diseases, tumour radiotherapy, chemotherapy or long-term application of diuretics. Combined with cardiovascular, cerebrovascular, hepatic, renal and haematopoietic system and other serious primary diseases, patients with mental diseases. (8) Patients with long-term or recent use of drugs affecting blood uric acid. (9) Rapid weight loss in the past 6 months, total parenteral nutrition and protein malnutrition. (10) Pregnant or lactating women (11) Allergy or intolerance to the ingredients of the investigational probiotic product; (12) Poor patient compliance and poor likelihood of follow-up;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal flora;Renal routine;Fecal flora genomics;hepatic function;Fecal routine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytokines: Interferon IFN - ? TNF-a,IL-1ß,IL-6,IL-10,IL-18; | — |
Countries
China
Contacts
Public ContactXiaohong Wu
Yixing People's Hospital
Outcome results
None listed